Up 13% in a month, Polynovo share price bounces back after being dumped from ASX 200

What's going on with the Polynovo share price?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The Polynovo share price has surged nearly 13% in a month 
  • In the past year, the company's share price has rocketed 50% 
  • Managers have been buying up Polynovo shares, potentially a sign of management confidence 

The Polynovo Ltd (ASX: PNV) share price has jumped ahead in the past month despite losing its place on the ASX 200.

The company's share price has jumped nearly 13% from $1.185 at market close on 3 June to the current price of $1.335. In contrast, the S&P/ASX 200 Index (ASX: XJO) has lost nearly 9% in the same time frame.

So why has the Polynovo share price had such a good month?

Two happy scientists analysing test results in a lab

Image source: Getty Images

Why has the Polynovo share price risen?

Polynovo is an ASX healthcare share working on medical devices, using patented technology Novosorb.

Polynovo shares have jumped amid insider trading among the company's management.

The company's chair David Williams bought $284,142 worth of shares on 6 June and 7 June alone. In total, he purchased 250,000 shares in these two days.

Williams has purchased more than $5 million worth of shares since the start of May, as my Foolish colleague Aaron reported.

Insider buying can be a sign that management is optimistic about the future direction of a company.

Polynovo reported record revenue of $12.6 million in the March quarter, up 59% compared to the same time in the previous year. The company's ANZ sales picked up substantially in the quarter, up 81.9% compared to the same time last year.

In recent news, Polynovo has completed settlement on the sale of its headquarters in Port Melbourne.

The company's headquarters sold for $6.35 million.

In recent times, Polynovo shares have made the list of the 10 most shorted ASX shares. However, as my Foolish colleague James reported, short interest in the company has eased to 7.9%.

Polynovo share price snapshot

The Polynovo share price has descended 50% in the past 12 months, while it is down 12% in the year to date.

In comparison, the benchmark ASX 200 has lost nearly 10% over the past year.

Polynovo has a market capitalisation of nearly $884 million based on today's share price.

Motley Fool contributor Monica O'Shea has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Young businesswoman sitting in kitchen and working on laptop.
Healthcare Shares

Up 15% in a week, is it too late to buy rebounding CSL shares?

CSL shares trade on roughly 13 times forecast FY26 earnings and offer a good dividend yield.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Broker Notes

Down 60%, are Cochlear shares now a bargain buy?

A leading analyst provides his outlook for Cochlear’s beaten-down shares.

Read more »

Young woman thinking with laptop open.
Healthcare Shares

Why are Sigma Healthcare shares in the spotlight this week?

Is the latest sell-off overdone?

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Is it time to get greedy with Pro Medicus shares?

The company was swept up in the huge sector-wide downturn in late 2025 and early 2026 as investors turned their…

Read more »

Young doctor raising arms in air with hands in fists celebrating a new development.
Healthcare Shares

Prediction: I think Telix shares could double in value in 2026. Here's why

The biopharmaceutical company's shares dipped to a three-year low in February, but have now rebounded strongly.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

How much does UBS think CSL will bounce back?

If the worst is over, what's the upside for the shares?

Read more »

Woman with long hair smiles for the camera.
Healthcare Shares

Why I'd buy CSL shares while sentiment is weak

The market no longer treats this ASX healthcare giant as flawless, and that may make the investment case more interesting.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Is this exciting healthcare stock a buy, hold or sell after rocketing 16% yesterday?

Can this soaring stock keep rising?

Read more »